ETRA
Electra Therapeutics, Inc.
Set alert
- YTD
- -38.87%
- 1 year
- -38.87%
- Open
- 8.39
- Prev close
- 8.64
- Mkt cap
- 508.41M
- Vol
- 150.60K
- Avg vol
- 636.20K
- EPS
- -2.65
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.95
- High
- 8.48
News
4 days ago benzinga.com
This FirstEnergy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Analysts initiated coverage on FE, ACCV, XE and ETRA, issuing Buy, Outperform, Equal-Weight and Hold ratings with targets up to $50.
-
4 days ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Electra Therapeutics with Buy Rating, Announces Price Target of $30
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Electra Therapeutics (NASDAQ:ETRA) with a Buy rating and announces Price Target of $30.
1 week ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…
-
1 week ago benzinga.com
Star Therapeutics Announces $200M Private Financing To Support Its Pipeline Of Potential Best-in-Disease Therapies
The financing follows the July 2026 acquisition of Star subsidiary Vega Therapeutics and was co-led by OrbiMed and Janus Henderson Investors, with participation from Agent Capital, Catalio Capital…
-
1 week ago benzinga.com
JP Morgan Initiates Coverage On Electra Therapeutics with Overweight Rating, Announces Price Target of $36
JP Morgan analyst Anupam Rama initiates coverage on Electra Therapeutics (NASDAQ:ETRA) with a Overweight rating and announces Price Target of $36.
-
2 weeks ago benzinga.com
Jefferies Initiates Coverage On Electra Therapeutics with Buy Rating, Announces Price Target of $32
Jefferies analyst Akash Tewari initiates coverage on Electra Therapeutics (NASDAQ:ETRA) with a Buy rating and announces Price Target of $32.
-
2 weeks ago benzinga.com
Evercore ISI Group Initiates Coverage On Electra Therapeutics with Outperform Rating, Announces Price Target of $36
Evercore ISI Group initiates coverage on Electra Therapeutics (NASDAQ:ETRA) with a Outperform rating and announces Price Target of $36.
2 weeks ago benzinga.com
This Electra Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts initiated coverage on NHP (Outperform, $20), OIG (Buy, $13), ETRA (Overweight), AHR (Strong Buy, $62).
-
2 weeks ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Electra Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Electra Therapeutics (NASDAQ:ETRA) with a Overweight rating.
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 106.0% to $0.15 during Wednesday's pre-market session. Connect Biopharma Hldgs (NASDAQ:CNTB) stock increased by 79.43% to $1.78. The…
1 month ago defenseworld.net
Electra Therapeutics (NASDAQ:ETRA) Director Carl Gordon Acquires 1,333,333 Shares of Stock
Electra Therapeutics, Inc. (NASDAQ: ETRA - Get Free Report) Director Carl Gordon bought 1,333,333 shares of the company's stock in a transaction that occurred on Monday, September 21st. The stock was…
1 month ago defenseworld.net
Electra Therapeutics (NASDAQ:ETRA) Director Orbimed Advisors Llc Purchases 1,333,333 Shares
Electra Therapeutics, Inc. (NASDAQ: ETRA - Get Free Report) Director Orbimed Advisors Llc bought 1,333,333 shares of the business's stock in a transaction on Monday, September 21st. The shares were…
1 month ago globenewswire.com
Kinzey Capital Management: Electra Sets Nasdaq IPO Terms
Kinzey Capital Management, based in Singapore, runs discretionary multi-asset portfolios serving private clients, corporates, families and foundations.
1 month ago globenewswire.com
Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines…
1 month ago reuters.com
Electra Therapeutics targets $977.6 million valuation in US IPO
Drug developer Electra Therapeutics is targeting a valuation of up to $977.6 million in its U.S. initial public offering, according to a filing on Monday, extending a comeback in biotech listings…